Unknown

Dataset Information

0

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.


ABSTRACT: This phase 1/2 study assessed the safety, tolerability, and preliminary efficacy of the oral proteasome inhibitor (PI) ixazomib in patients with relapsed/refractory immunoglobulin light chain (AL) amyloidosis. Ixazomib was administered to adult patients with relapsed/refractory AL amyloidosis after 1 or more prior lines of therapy (including bortezomib) on days 1, 8, and 15 of 28-day cycles, for up to 12 cycles. Patients with less than partial response after 3 cycles received oral dexamethasone (40 mg, days 1-4) from cycle 4. A 3+3 dose-escalation phase was followed by 2 expansion cohorts (PI-naive and PI-exposed patients) at the maximum tolerated dose (MTD). Twenty-seven patients were enrolled: 11 during dose escalation (6 at 4.0 mg and 5 at 5.5 mg) and 16 during dose expansion (4.0 mg). Three patients experienced dose-limiting toxicities: 1 at 4.0 mg and 2 at 5.5 mg; the MTD was determined as 4.0 mg. Most common adverse events (AEs) included nausea, skin and subcutaneous tissue disorders (SSTD), diarrhea, and fatigue; grade 3 or higher AEs included dyspnea, fatigue, and SSTD. Overall, the hematologic response rate was 52% in patients treated at the MTD (n = 21). Organ responses were seen in 56% of patients (5 cardiac, 5 renal). Median hematologic progression-free survival was 14.8 months; 1-year progression-free and overall survival rates were 60% and 85%, respectively (median follow-up, 16.9 months). Weekly oral ixazomib appears to be active in patients with relapsed/refractory AL amyloidosis, with a generally manageable safety profile. The study was registered at clinicaltrials.gov as #NCT01318902 A phase 3 study is ongoing (#NCT01659658).

SUBMITTER: Sanchorawala V 

PROVIDER: S-EPMC6911836 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4220649 | BioStudies
2014-01-01 | S-EPMC4468583 | BioStudies
2015-01-01 | S-EPMC4559079 | BioStudies
2016-01-01 | S-EPMC4859859 | BioStudies
2017-01-01 | S-EPMC5610674 | BioStudies
2017-01-01 | S-EPMC5622861 | BioStudies
2017-01-01 | S-EPMC5729338 | BioStudies
2009-01-01 | S-EPMC2799050 | BioStudies
2015-01-01 | S-EPMC4435632 | BioStudies
2016-01-01 | S-EPMC4731845 | BioStudies